Thyrotropic effects of balneotherapy in Truskavets’ spa and their endocrine, vegetative and metabolic accompaniments

Sofiya V. Ruzhylo1, Nataliya R. Zakalyak2, Dariya V. Popovychn3, Volodymyr V. Kikhtan3, Teodor S. Seniv3, Oksana N. Novak3, Oksana I. Mats’ko4, Xawery Żukow4

1Ivan Franko State Pedagogical University, Drohobych, Ukraine
doctor-0701@ukr.net  natalyazak69@gmail.com

2IY Horbachevs’kyi National Medical University, Ternopil’, Ukraine
darakoz@yahoo.com

3Clinical Sanatorium “Moldova”, Truskavets’, Ukraine san.moldova.tr@ukr.net

4Medical University of Białystok, Białystok, Poland xaweryzukow@gmail.com

Abstract

Background. Previous studies of the Truskavetsian Scientific School of Balneology have studied the effects of course use of bioactive water Naftussya - the main therapeutic factor of the spa - on plasma levels of thyroid hormones in males and females healthy rats and women with thyroid hyperplasia. In men with chronic cholecystitis, the immediate thyrotropic effects of a single use of Naftussya water have been studied. The aim of this study is thyrotropic effects of balneotherapy in Truskavets’ spa and their endocrine, vegetative and metabolic accompaniments in men and women with chronic cholecystitis and pyelonephritis. Materials and Methods. The object of clinical-physiological observation were 34 men (23-70 years) and 10 women (39-76 years), who underwent rehabilitation treatment of chronic cholecystitis and pyelonephritis in remission in the Truskavets’ spa. The examination was performed twice, before and after a 7-10-day course of balneotherapy. The main object of study was the plasma level of Triiodothyronine. We determined also content in plasma Cortisol, Aldosterone, Testosterone and Calcitonin as well as the parameters of the HRV and metabolism. Results. We find in 16 patients (12 men and 4 women) inhibitory thyrotropic effect, in 22 (16 men and 6 women) neutral, and in 6 men only – enhancing effect of balneotherapy. Each variant of the
thyrotropic effect is accompanied by characteristic changes in testosteronemia, calcitoninemia, parathyroid activity, Heart Rate, Baevskiy’s Activity Regulatory Systems Index, HRV-markers of vagal tone, Calciemia as well as VLD and LD lipoproteins Cholesterol plasma. **Conclusion.** Our data confirmed and supplemented the provisions on the multivariate effects of balneotherapy in the spa of Truskavets’ on the endocrine and autonomic nervous systems and metabolism of patients.

**Keywords:** Truskavets’ spa, chronic cholecystitis and pyelonephritis, endocrine, HRV, metabolic parameters.

**INTRODUCTION**

Previous investigations of the Truskavetsian Scientific School of Balneology have studied the effects of course use of bioactive water Naftussya - the main therapeutic factor of the spa - on plasma levels of thyroid hormones in males [12-15,21] and females [17,21,31] healthy rats and women with thyroid hyperplasia [4,6,16,19,21,27,28,30]. In men with chronic cholecystitis, the immediate thyrotropic effects of a single use of Naftusya water have been studied [18,20,21]. The aim of this study is thyrotropic effects of balneotherapy in Truskavets’ spa and their endocrine, vegetative and metabolic accompaniments in men and women with chronic cholecystitis and pyelonephritis.

**MATERIALS AND METHODS**

The object of clinical-physiological observation were 34 men (23-70 ys) and 10 women (39-76 ys), who underwent rehabilitation treatment in the Truskavets’ spa of chronic cholecystitis and pyelonephritis in remission with neuroendocrine-immune complex dysfunction. The examination was performed twice, before and after a 7-10-day course of balneotherapy.

The main object of study was the plasma levels of Triiodothyronine. We determined also content in plasma Cortisol, Aldosterone, Testosterone and Calcitonin (by the ELISA with the use of analyzer “RT-2100C” and corresponding sets of reagents from “Алкор Био”, XEMA Co., Ltd and DRG International Inc.).

In basal conditions we estimated the state of the autonomous regulation by the method heart rate variability (HRV) [1,3,10,29], using a hardware-programmatic complex "CardioLab+HRV" (KhAI Medica, Kharkiv, Ukraine). The following parameters were object to analysis. Frequency Domain Methods: HF (0,4÷0,15 Hz), LF (0,15÷0,04 Hz), VLF (0,04÷0,015 Hz), ULF (0,015÷0,003 Hz) bands. Time Domain Methods: HR, Triangular Index, SDNN, RMSSD, pNN50. Calculated also Baevskiy’s Activity Regulatory Systems Index (BARSII) [1].

The day before, daily urine was collected, in which was determined the concentration of calcium (by reaction with arsenase III) and phosphates (phosphate-molybdate method).

The same metabolic parameters were determined in plasma as well as magnesium (by reaction with colgamite), chloride (mercury-rhodanidine method), sodium and potassium (flamming photometry), creatinine (by Jaffé's color reaction by Popper's method), urea.
(urease method by reaction with phenolhypochlorite), uric acid (uricase method), triglycerides (by a certain meta-periodate method), total cholesterol (by a direct method after the classic reaction by Zlatkis-Zack) and content of him in composition of HD lipoproteins (by the enzyme method after precipitation of VLD and LD lipoproteins); VLD lipoproteins (expected by the level of triglycerides); LD lipoproteins (expected by a difference between a total cholesterol and cholesterol in composition HD and VLD lipoproteins).

The analysis carried out according to instructions [7] with the use of analyzers "Reflotron" (BRD) and "Pointe-180" (USA) and corresponding sets of reagents, as well as the flaming spectrophotometer “CФ-47”.

According to the parameters of calcium and phosphates exchange, parathyroid activity was evaluated by coefficient (Cap•Pu/Cau•Рп)$^{0.25}$, based on its classical effects and recommendations by Popovych IL [9,23-26].

Normal (reference) values of variables are taken from the database of the Truskavetsian Scientific School of Balneology.

For statistical analysis used the software package "Statistica 64".

RESULTS AND DISCUSSION

Preliminary analysis of direct differences between plasma levels of triiodothyronine after and before balneotherapy revealed both negative (in the majority) and positive (in the minority) changes. This is quite expected, based on previous studies of the thyrotropic effects of balneotherapy. Unlike previous authors, we have expanded the range of insignificant (neutral) changes from ±0,5σ to ±σ. Accepting this gradation, we find in 16 patients (12 men and 4 women) inhibitory thyrotropic effect, in 22 (16 men and 6 women) neutral, and in 6 men only - enhancing.

To identify these parameters, changes in which are characteristic of polyvariant thyrotropic effects, a discriminant analysis [11] of registered indicators was conducted. The program forward stepwise included in the discriminant model, except triiodothyronine by definition, 9 variables: 3 autonomous (HRV), 3 endocrine and 3 metabolic (Tables 1 and 3). Given the drastic gender differences in plasma levels testosterone (average 14,8 and 2,30 nM/L) and calcitonin (average 13,95 and 5,50 ng/L), they were expressed in Z-units for a correct estimate: $Z=(V/N-1)/Cv$ [8,25,31].
Table 1. Summary of the analysis of discriminant functions in relation to the change in neuro-endocrine and metabolic parameters

Step 10, N of vars in model: 10; Grouping: 3 grps; Wilks' Λ: 0.0644; approx. F(23)=8.3; p<10^-6

| Variables currently in the model | Groups of changes (Men/Women) | Parameters of Wilks' Statistics |
|----------------------------------|-------------------------------|--------------------------------|
|                                  | Thyroid + (6/0) | Thyroid ± (16/6) | Thyroid - (12/4) | Wilks’ Λ | Partial Λ | F-remove (2.31) | p-level | Tolerance | Norm Cv |
|----------------------------------|----------------|----------------|----------------|---------|----------|----------------|---------|------------|---------|
| Triiodothyronine Plasma, nM/L    | 1.83           | 2.78           | 2.64           | 0.342   | 0.188    | 66.8          | 10^-6   | 0.661      | 2.20    | 0.227    |
|                                  | 2.78           | 1.75           | 1.74           |         |          |                |         |            |         |         |
|                                  | +0.96          | -0.04          | -0.90          |         |          |                |         |            |         |         |
| Baevskiy’s Activity Regulatory Systems Index, units | 3.47 | 3.63 | 4.22 | 0.070 | 0.915 | 1.43 | 0.254 | 0.752 | 1.5 | 0.500 |
|                                  | 2.64           | 2.52           | 2.39           |         |          |                |         |            |         |         |
|                                  | +0.15          | -0.13          | -1.83          |         |          |                |         |            |         |         |
| ULF band HRV Spectral Power, msec² | 59             | 126            | 101            | 0.074   | 0.866    | 2.40           | 0.107   | 0.561      | 122     | 0.892    |
|                                  | 126            | 132            | 132            |         |          |                |         |            |         |         |
|                                  | +67            | +67            | +67            |         |          |                |         |            |         |         |
| Testosterone standardized by sex and age, Z | +0.62 | +1.23 | +0.36 | 0.074 | 0.876 | 2.20 | 0.127 | 0.257 | 0 | 0.400 |
|                                  | -0.74          | +0.15          | -0.28          |         |          |                |         |            |         |         |
|                                  | -1.37          | -1.08          | -0.64          |         |          |                |         |            |         |         |
| VLD Cholesterol Plasma, mM/L     | 0.66           | 0.013          | 0.41           | 0.085   | 0.759    | 4.93           | 0.014   | 0.558      | 0.54    | 0.612    |
|                                  | 0.79           | 0.49           | 0.60           |         |          |                |         |            |         |         |
|                                  | +0.13          | -0.13          | +0.18          |         |          |                |         |            |         |         |
| Heart Rate, beats/min            | 74.1           | 70.2           | 65.8           | 0.077   | 0.835    | 3.06           | 0.061   | 0.712      | 68.4    | 0.120    |
|                                  | 77.6           | 69.9           | 69.7           |         |          |                |         |            |         |         |
|                                  | +3.5           | -0.4           | +4.0           |         |          |                |         |            |         |         |
| Parathyroid activity, units      | 1.72           | 1.83           | 1.81           | 0.070   | 0.921    | 1.34           | 0.277   | 0.741      | 1.82    | 0.230    |
|                                  | 1.77           | 1.82           | 1.83           |         |          |                |         |            |         |         |
|                                  | +0.05          | -0.01          | +0.02          |         |          |                |         |            |         |         |
| LD Cholesterol Plasma, mM/L      | 3.13           | 3.57           | 3.71           | 0.067   | 0.963    | 0.59           | 0.561   | 0.666      | 3.48    | 0.192    |
|                                  | 2.44           | 3.77           | 3.09           |         |          |                |         |            |         |         |
|                                  | -0.68          | +0.20          | -0.61          |         |          |                |         |            |         |         |
| Calcitonin standardized by sex, Z | -0.85 | -0.97 | -0.63 | 0.079 | 0.817 | 3.48 | 0.043 | 0.698 | 0 | 0.493 |
|                                  | -0.96          | -0.37          | -0.60          |         |          |                |         |            |         |         |
|                                  | -0.11          | +0.60          | +0.03          |         |          |                |         |            |         |         |
| Calcium Plasma, mM/L             | 2.19           | 2.21           | 2.19           | 0.074   | 0.874    | 2.24           | 0.123   | 0.504      | 2.30    | 0.065    |
|                                  | 2.15           | 2.23           | 2.17           |         |          |                |         |            |         |         |
|                                  | -0.04          | +0.02          | -0.02          |         |          |                |         |            |         |         |

Notes. In each column, the first line is the average initial, the second – final, the third – direct difference. In the “Norm” column, the first row is average, the second row is Cv. Only direct differences (effects) are the object of discriminant analysis.
Table 2. Summary of stepwise analysis of discriminant variables ranked by criterion \( \Lambda \)

| Variables currently in the model                        | F to enter | p-level | \( \Lambda \) | F-value | p-level |
|----------------------------------------------------------|------------|---------|---------------|---------|---------|
| Triiodothyronine Plasma, nM/L                            | 83.8       | 10\(^{-6}\) | 0.196        | 83.9    | 10\(^{-6}\) |
| LD Cholesterol Plasma, mM/L                             | 4.30       | 0.020   | 0.162        | 29.7    | 10\(^{-6}\) |
| VLD Cholesterol Plasma, mM/L                            | 2.65       | 0.084   | 0.142        | 21.5    | 10\(^{-6}\) |
| Calcitonin standardized by sex, Z                       | 2.82       | 0.072   | 0.124        | 17.5    | 10\(^{-6}\) |
| Heart Rate, beats/min                                   | 2.02       | 0.147   | 0.112        | 14.7    | 10\(^{-6}\) |
| Testosterone standardized by sex and age, Z             | 2.30       | 0.115   | 0.091        | 11.6    | 10\(^{-6}\) |
| Baevskiy's Activity RS Index, units                     | 1.26       | 0.298   | 0.084        | 10.4    | 10\(^{-6}\) |
| Parathyroid activity, units                              | 1.15       | 0.328   | 0.079        | 9.39    | 10\(^{-6}\) |
| ULF band HRV Spectral Power, msec\(^{2}\)               | 1.10       | 0.344   | 0.074        | 8.58    | 10\(^{-6}\) |
| Calcium Plasma, mM/L                                     | 2.24       | 0.123   | 0.064        | 8.28    | 10\(^{-6}\) |

A number of variables, despite their recognizable properties, were outside the discriminant model (Tables 3 and 4).

Table 3. Neuroendocrine parameters currently not in the model

| Variables                          | Groups of changes (Men/Women) | Parameters of Wilks' Statistics |
|------------------------------------|-------------------------------|--------------------------------|
|                                    | Thyr + (6/0)                  | Wilks \( \Lambda \) | Partial \( \Lambda \) | F to enter | p-level | Tolerance | Norm Cv (30) |
| Triangular Index HRV, units        | 9.5                            | 0.064 | 0.898        | 0.17 | 0.841 | 0.532 | 11.2 | 0.217 |
|                                    | 12.4                           |                  | 10.3        | -2.2 |
|                                    | 11.2                           |                  | 12.5        | 10.1 |
|                                    | +2.9                           |                  | +1.1        |       |
|                                    | 55                             |                  | 55          | 44   |
|                                    | 45                             |                  |             |       |
|                                    | 50                             |                  |             |       |
|                                    | +5                             |                  |             |       |
| SDNN HRV, msec                     | 39                             | 0.064 | 0.990        | 0.14 | 0.866 | 0.465 | 56   | 0.516 |
|                                    | 53                             |                  | 55          | 44   |
|                                    | +14                            |                  |             |       |
|                                    | 26.2                           | 0.063 | 0.984        | 0.24 | 0.788 | 0.575 | 28.8 | 0.486 |
|                                    | 28.3                           |                  | 34.5        | 27.7 |
|                                    | +10.6                          |                  |             | -6.8 |
|                                    | 26                             |                  |             |       |
|                                    | +4                             |                  |             |       |
|                                    | 9.5                            | 0.063 | 0.983        | 0.27 | 0.768 | 0.563 | 9.0  | 0.820 |
|                                    | 9.6                            |                  | 13.3        | 9.5  |
|                                    | +0.8                           |                  |             | -3.9 |
| RMSSD HRV, msec                    | 1.2                            | 0.060 | 0.983        | 0.27 | 0.768 | 0.563 | 9.0  | 0.820 |
|                                    | 8.1                            |                  | 13.3        | 9.5  |
|                                    | +6.9                           |                  |             | -3.9 |
| Total Power HRV, msec\(^{2}\)      | 1570                           | 0.064 | 0.991        | 0.14 | 0.874 | 0.448 | 2379 | 0.402 |
|                                    | 3059                           |                  | 3367        | 2286 |
|                                    | +1490                          |                  |             | -1081|
|                                    | 1067                           | 0.064 | 0.992        | 0.12 | 0.891 | 0.696 | 1250 | 0.572 |
|                                    | 1176                           |                  | 1639        | 940  |
|                                    | +110                           |                  |             | -700 |
|                                    | 1235                           |                  |             |       |
|                                    | 837                            |                  |             |       |
|                                    | +397                           |                  |             |       |
| VLF HRV PS, msec\(^{2}\)           | 633                            | 0.061 | 0.951        | 0.77 | 0.474 | 0.510 | 625  | 0.482 |
|                                    | 1264                           |                  | 1235        | 837  |
|                                    | +631                           |                  |             | -397 |
|                                    | 771                            | 0.061 | 0.951        | 0.77 | 0.474 | 0.510 | 625  | 0.482 |
|                                    | 856                            |                  | 1235        | 837  |
|                                    | +85                            |                  |             | -397 |
| HF HRV PS, msec\(^{2}\)            | 111                            | 0.063 | 0.973        | 0.42 | 0.659 | 0.496 | 350  | 0.713 |
|                                    | 373                            |                  | 560         | 446  |
|                                    | +262                           |                  |             | -114 |
|                                    | 419                            | 0.063 | 0.973        | 0.42 | 0.659 | 0.496 | 350  | 0.713 |
|                                    | 565                            |                  | 560         | 446  |
|                                    | +146                           |                  |             | -114 |
| Aldosterone Plasma, pM/L           | 221                            | 0.062 | 0.963        | 0.58 | 0.567 | 0.814 | 238  | 0.187 |
|                                    | 232                            |                  | 223         | 227  |
|                                    | +11                            |                  |             | +4   |
|                                    | 227                            | 0.062 | 0.963        | 0.58 | 0.567 | 0.814 | 238  | 0.187 |
|                                    | 233                            |                  | 223         | 227  |
|                                    | +6                             |                  |             | +4   |
| Cortisol Plasma, nM/L              | 360                            | 0.064 | 0.992        | 0.11 | 0.892 | 0.759 | 370  | 0.303 |
|                                    | 478                            |                  | 381         | 419  |
|                                    | +117                           |                  |             | +38  |
|                                    | 371                            | 0.064 | 0.992        | 0.11 | 0.892 | 0.759 | 370  | 0.303 |
### Table 4. Metabolic parameters currently not in the model

| Variables                  | Groups of changes (Men/Women) | Parameters of Wilks' Statistics | Norm Cv (30) |
|----------------------------|-------------------------------|--------------------------------|--------------|
| Calcium Urine, mM/L        |                               |                                |              |
|                            | Thyr + (6/0)                  | 2.65                           |              |
|                            | Thyr ± (16/6)                 | 2.53                           |              |
|                            | Thyr - (12/4)                 | 2.45                           |              |
|                            | Wilks Λ                        | 0.064                          |              |
|                            | Partial Λ                     | 0.991                          |              |
|                            | F to enter                    | 0.14                           |              |
|                            | p-level                       | 0.872                          |              |
|                            | Tolerance                     | 0.298                          |              |
|                            |                                | 3.13                           |              |
|                            |                                | 0.214                          |              |
| Phosphates Urine, mM/L     |                               |                                |              |
|                            | 10.1                          | 9.9                            |              |
|                            | 11.5                          | 13.5                           |              |
|                            | +1.4                          | +3.6                           |              |
| Phosphate Plasma, mM/L     |                               |                                |              |
|                            | 1.03                          | 1.03                           |              |
|                            | 0.96                          | 1.01                           |              |
| Magnesium Plasma, µM/L     |                               |                                |              |
|                            | 824                           | 849                            |              |
|                            | 806                           | 829                            |              |
| Potassium Plasma, mM/L     |                               |                                |              |
|                            | 4.01                          | 4.28                           |              |
|                            | 4.11                          | 4.48                           |              |
|                            | +0.10                         | +0.20                          |              |
| Chloride Plasma, mM/L      |                               |                                |              |
|                            | 97.9                          | 99.9                           |              |
|                            | +2.0                          | +0.9                           |              |
| Sodium Plasma, mM/L        |                               |                                |              |
|                            | 138.0                         | 144.4                          |              |
|                            | 140.5                         | 145.5                          |              |
| Creatinine Plasma, µM/L    |                               |                                |              |
|                            | 93.0                          | 92.1                           |              |
|                            | 86.3                          | 83.4                           |              |
| Uric acid Plasma, µM/L     |                               |                                |              |
|                            | 289                           | 355                            |              |
|                            | 295                           | 345                            |              |
| Total Cholesterol Plasma, mM/L |                               |                                |              |
|                            | 4.95                          | 5.60                           |              |
|                            | 4.40                          | 5.67                           |              |
| HD Cholesterol Plasma, mM/L |                               |                                |              |
|                            | 1.17                          | 1.41                           |              |
|                            | 1.17                          | 1.41                           |              |
|                            | 0.00                          | 0.00                           |              |

The identifying information contained in the 10 discriminant variables is condensed into two roots. The major root contains 84.3% of discriminatory opportunities ($r^*=0.928$; Wilks' Λ=0.064; $\chi^2_{(22)}=99$; $p<10^{-6}$), while minor root – 15.7% only ($r^*=0.732$; Wilks' Λ=0.464; $\chi^2_{(10)}=28$; $p=0.002$).

Calculating the values of discriminant roots for each patient as the sum of the products of non-standardized (raw) coefficients for individual values of discriminant variables together with the constant (Table 5) allows visualization of each patient in the information space of roots (Fig. 1).
Table 5. Standardized and raw coefficients and constants for discriminant variables

| Variables                              | Coefficients | Standardized | Raw |
|----------------------------------------|--------------|--------------|-----|
|                                        | Root 1       | Root 2       | Root 1 | Root 2 |
| Triiodothyronine Plasma, nM/L          | -1.185       | 0.181        | -3.794 | 0.581 |
| LD Cholesterol Plasma, mM/L            | 0.092        | -0.298       | 0.096  | -0.311 |
| VLD Cholesterol Plasma, mM/L           | 0.183        | 0.868        | 0.560  | 2.662 |
| Calcitonin standardized by sex, Z      | -0.165       | -0.668       | -0.156 | -0.636 |
| Heart Rate, beats/min                  | -0.277       | 0.555        | -0.029 | 0.058 |
| Testosterone standardized by sex and age, Z | 0.019        | 0.951        | 0.019  | 0.954 |
| Baevsky’s Activity RS Index, units     | -0.165       | -0.407       | -0.070 | -0.172 |
| Parathyroid activity, units            | 0.249        | -0.317       | 0.742  | -0.948 |
| ULF band HRV Spectral Power, msec²     | -0.525       | -0.063       | -0.0029 | -0.0003 |
| Calcium Plasma, mM/L                   | 0.536        | 0.081        | 2.900  | 0.440 |

| Constants                              |              |              |      |
|----------------------------------------|--------------|--------------|-----|
| Cumulative Proportion                  | 0.843        | 1            |     |

Table 6 collects the Z-scores of discriminant variables together with those that are not included in the model, but still reflect the specificity of effects. This approach makes it possible to describe in more detail the neuro-endocrine and metabolic accompaniments of thyrotropic effects of balneotherapy.

Table 6. Correlations between change in variables and roots, centroids of clusters and Z-scores of clusters

| Variables                              | Correlations Variables-Roots | Thyr + (6) | Thyr ± (22) | Thyr - (16) |
|----------------------------------------|------------------------------|------------|-------------|-------------|
| Root 1(84.3 %)                         | Root 1 Root 2                | -0.42      | -0.81       | +2.77       |
| Triiodothyronine Plasma                | 0.011                       | 0.086      | +1.91       | -0.07       | -1.80       |
| LF band HRV Spectral Power             | +2.50                       | +0.39      | -1.61       |             |
| pNNs HRV                               | +1.14                       | +0.08      | -0.59       |             |
| HF band HRV Spectral Power             | +1.57                       | +0.52      | -0.54       |             |
| RMSSD HRV                              | +0.96                       | +0.34      | -0.56       |             |
| Triangular Index HRV                   | +1.20                       | +0.47      | -0.89       |             |
| VLF band HRV Spectral Power            | +0.84                       | +0.14      | -0.98       |             |
| SDNN HRV                               | +0.51                       | +0.18      | -0.33       |             |
| Baevsky’s Activity Regulatory Systems Ind | -0.137                   | -0.137     | +0.21       | -0.17       | -2.44       |
| ULF band HRV Spectral Power            | -0.095                      | -0.126     | +0.62       | +0.62       | -0.34       |
| Testosterone standardized by sex and age | 0.107                     | 0.034      | -1.37       | -1.08       | -0.64       |
| Root 2(15.7 %)                         | Root 1 Root 2                | +1.78      | -0.98       | +0.68       |
| VLD Cholesterol Plasma                 | 0.086                       | 0.406      | +0.37       | -0.34       | +0.53       |
| Heart Rate                             | 0.035                       | 0.192      | +0.42       | -0.05       | +0.49       |
| Parathyroid activity                   | -0.005                      | 0.037      | +0.11       | -0.01       | +0.05       |
| Creatinine Plasma                      | -0.50                       | -0.65      | -0.24       |             |
| Uric acid Plasma                       | +0.08                       | -0.13      | +0.25       |             |
| Chloride Plasma                        | +0.61                       | +0.27      | +1.55       |             |
| Sodium Plasma                          | +0.50                       | +0.22      | +1.28       |             |
| LD Cholesterol Plasma                  | -0.052                      | -0.403     | -1.13       | +0.31       | -0.97       |
| Calcitonin standardized by sex         | -0.024                      | -0.274     | -0.11       | +0.60       | +0.03       |
| Calcium Urine                          | -0.18                       | +0.87      | +0.39       |             |
| Phosphates Urine                       | +0.26                       | +0.69      | +0.18       |             |
| Potassium Plasma                       | +0.22                       | +0.43      | -0.08       |             |
| Calcium Plasma                         | -0.004                      | -0.121     | -0.24       | +0.15       | -0.11       |
| Phosphates Plasma                      | -0.33                       | -0.08      | -0.41       |             |
| Urea Plasma                            | -0.30                       | -0.11      | -0.30       |             |
| Total Cholesterol Plasma               | -0.58                       | +0.07      | -0.47       |             |
The first root represents changes in plasma triiodothyronine levels in the inverse way, so the cluster of patients subject to inhibitory thyrotropic effect is located in the extreme right zone of the root axis. This direction of the thyrotropic effect is accompanied by a significant decrease in the index of activity of regulatory systems, apparently due to parasympathetic, markers of which were not included in the discriminant model, apparently due to duplication and/or redundancy of information. At the opposite pole of the axis are the members of the cluster of enhancing thyrotropic effect, which is accompanied by an increase in vagal tone. And intermediate position is occupied by patients with insignificant changes in both triiodothyronine levels and vagal tone. Instead, changes in testosterone levels correlate with the root directly, so that the enhancing thyrotropic effect is accompanied by a maximum reduction in testosterone, the neutral effect - an intermediate reduction, and the inhibitory effect - the minimum for sampling reduction.

As we can see, all three clusters are quite clearly delineated along the axis of the major root. However, the cluster of neutral thyrotropic effect of balneotherapy is further different from the other two along the minor root axis. The lowest localization of the cluster reflects the decrease or absence of significant changes in the parameters that are directly related to the root, while both inhibitory and enhancing thyrotropic effects are accompanied by increasing levels of these parameters. Conversely, inversely related root parameters in patients with a neutral thyrotropic effect increase as much as possible for the sample or do not change, whereas in the other two clusters they are significantly lower.

Interestingly, changes in calcitonin levels are accompanied by corresponding changes in urinary calcium and phosphate concentrations, but not in plasma.

![Fig. 1. Scattering of individual values of the roots of patients with enhancing, neutral and inhibitory thyrotropic effects of balneotherapy](image)

The visual impression of a clear demarcation of the three clusters in the information field of the two roots is documented by calculating the distances of Mahalanobis (Table 7).
Table 7. Squares of Mahalanobis distances between clusters (above the diagonal) as well as F-criteria (df=11.3) and p-levels (below the diagonal)

| Clusters | Thyr + | Thyr - | Thyr ± |
|----------|--------|--------|--------|
| Thyr + (6) | 0      | 53     | 21     |
| Thyr - (16) | 15,9   | 0      | 16     |
| Thyr ± (22) | 6,7    | 9,9    | 0      |

Selected discriminant variables were used to identify the affiliation of a patient to a particular cluster. This goal of discriminant analysis is realized with the help of classification functions (Table 8).

Table 8. Coefficients and constants of classification functions

| Variables                          | Clusters | Thyr + | Thyr - | Thyr ± |
|------------------------------------|----------|--------|--------|--------|
| Triiodothyronine Plasma, nM/L      | p=.136   | p=.364 | p=.500 |
| LD Cholesterol Plasma, mM/L        | -1,328   | -0,295 | -0,125 |
| VLD Cholesterol Plasma, mM/L       | 3,560    | 4,648  | -1,753 |
| Calcitonin standardized by sex, Z  | -0,164   | -0,587 | 1,023  |
| Heart Rate, beats/min              | 0,216    | -0,055 | -0,047 |
| Testosterone standardized by sex and age, Z | 0,599   | -0,320 | -1,964 |
| Baevskiy’s Activity RS Index, units | -0,190  | -0,501 | 0,031  |
| Parathyroid activity, units        | -4,823   | 1,564  | 0,476  |
| ULF band HRV Spectral Power, msec² | 0,013    | -0,008 | 0,003  |
| Calcium Plasma, mM/L               | -8,495   | 11,88  | 0,782  |
| Constants                          | -10,78   | -9,09  | -1,99  |

Retrospective identification of all clusters is very accurate: with only one error (Table 9).

Table 9. Classification matrix

Rows: observed classifications; columns: projected classifications

| Clusters | Percent Correct | Thyr + | Thyr - | Thyr ± |
|----------|----------------|--------|--------|--------|
| Thyr +   | 100            | 6      | 0      | 0      |
| Thyr -   | 93,8           | 0      | 15     | 1      |
| Thyr ±   | 100            | 0      | 0      | 22     |
| Total    | 97,7           | 6      | 15     | 23     |

**CONCLUSION**

Our data confirm and supplement the previous data on the polyvariance of thyrotropic effects of Naftusya bioactive water in healthy rats and patients of Truskavets’ resort of both sexes. Such polyvariance is a separate manifestation of the polyvariance effect of balneotherapy on other body systems [2, 5, 8, 21, 28, 30, 31]. We confirmed and supplemented data on characteristic changes in other endocrine, HRV and metabolic parameters that interact closely within the neuroendocrine-immune complex [8, 9, 21, 22, 24, 26].
ACKNOWLEDGMENT

We express sincere gratitude to TA Korolyshyn as well as administration of clinical sanatorium “Moldova” for help in recording tests.

ACCORDANCE TO ETHICS STANDARDS

Tests in patients are carried out in accordance with positions of Helsinki Declaration 1975, revised and complemented in 2002, and directive of National Committee on ethics of scientific researches. During realization of tests from all participants the informed consent is got and used all measures for providing of anonymity of participants.

REFERENCES

1. Baevsky RM, Ivanov GG. Heart Rate Variability: theoretical aspects and possibilities of clinical application [in Russian]. Ultrasound i funktionalnaya diagnostika. 2001; 3: 106-127.
2. Balanovs’kyi VP, Popovych IL, Karpynets’ SV. About ambivalence-equilibratory character of influence of curative water Naftussya on organism of human [in Ukrainian]. Dopovidi ANU. Mat pry dr Nauky. 1993; 3: 154-158.
3. Bernston GG, Bigger JT jr, Eckberg DL, Grossman P, Kaufman PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, Van der Molen MW. Heart Rate Variability: Origins, methods, and interpretive caveats. Psychophysiology. 1997; 34: 623-648.
4. Bul’ba AYa. Types of thyrotropic effects of balneotherapy in Truskavets’ spa, their neuro-endocrine and clinical companions and predictors in women with hyperplasia of the thyroid gland [in Ukrainian]. Medical Hydrology and Rehabilitation. 2007; 5(2): 30-45.
5. Chebanenko OI, Chebanenko LO, Popovych IL. Variety Balneoeffects of Factors Spa Truskavets’ and their Forecast [in Ukrainian]. Kyiv. UNESCO-SOCIO; 2012: 496.
6. Fuchko OL, Bul’ba AYa. Types of thyrotropic effects of balneotherapy at the spa of Truskavets’ in women with hyperplasia of the thyroid gland and concomitant changes in lipid and electrolyte metabolism [in Ukrainian]. Medical Hydrology and Rehabilitation. 2008; 6(3): 51-59.
7. Goryachkovskiy AM. Clinical Biochemistry [in Russian]. Odesa. Astroprint; 1998: 608.
8. Gozhenko AI, Korda MM, Popadynets’ OO, Popovych IL. Entropy, Harmony, Synchronization and Their Neuro-Endocrine-Immune Correlates [in Ukrainian]. Odesa. Feniks; 2021: 232.
9. Gozhenko AI, Zukow W, Polovynko IS, Zajats LM, Yanchij RI, Portnichenko VI, Popovych IL. Individual Immune Responses to Chronic Stress and their Neuro-Endocrine Accompaniment. RSW. UMK. Radom. Torun; 2019: 200.
10. Heart Rate Variability. Standards of Measurement, Physiological Interpretation, and Clinical Use. Task Force of ESC and NASPE. Circulation. 1996; 93(5): 1043-1065.
11. Klecka WR. Discriminant Analysis [trans. from English in Russian] (Seventh Printing, 1986). In: Factor, Discriminant and Cluster Analysis. Moskva: Finansi i Statistika; 1989: 78-138.
12. Kozyavkina NV. Variants of thyrotropic effects of Naftussya bioactive water and their lipid accompaniment [in Ukrainian]. Medical Hydrology and Rehabilitation. 2008; 6(3): 115-122.
13. Kozyavkina NV. Variantes of thyrotropic effects of bioactive water Naftussya and its lipid accompaniment. International Scientific Congress and 61-st Session of the General Assembly of the World Federation of Hydrotherapy and Climatotherapy (FEMTEC). Congress materials (China, November 26-28, 2008): 221-222.
14. Kozyavkina NV. Neuro-endocrine and electrolyte accompaniments of polyvariant thyrotropic effects of bioactive water Naftussya [in Ukrainian]. Medical Hydrology and Rehabilitation. 2009; 7(1): 51-55.
15. Kozyavkina NV. Immune accompaniment of polyvariant thyrotropic effects of bioactive water Naftusya in rats [in Ukrainian]. Medical Hydrology and Rehabilitation. 2009; 7(2): 27-39.
16. Kozyavkina NV. Polyvariance of thyrotropic effects of Naftussya bioactive water in women with chronic endocrine and gynecological pathology, their neuroendocrine-immune and clinical accompaniments and prognostic possibilities [in Ukrainian]. Medical Hydrology and
17. Kozyavkina NV. Thyrotropic effects of Naftusya bioactive water in female rats and their metabolic, neuroendocrine and immune accompaniment [in Ukrainian]. Medical Hydrology and Rehabilitation. 2012; 10(4): 91-113.

18. Kozyavkina NV, Gozhenko AI, Barylyak LG, Korolyshyn TA, Popovych IL. Polyvariance of immediate thyrotropic effects of Naftussya bioactive water, their neuroendocrine-immune support and predictability [in Ukrainian]. Medical Hydrology and Rehabilitation. 2013; 11(4): 27-54.

19. Kozyavkina NV, Popovych IL, Zukow W. Metabolic accompaniment of thyrotropic effects of bioactive water Naftussya at the women with thyroid hyperplasia. Journal of Health Sciences. 2013; 3(5): 409-424.

20. Kozyavkina NV, Yanchij OR, Fuchko OL. Thyrotropic effects of Naftussya water, their vegetative manifestation and predictability [in Ukrainian]. Fiziol Zh. 2013; 59(6): 81-87.

21. Kozyavkina OV, Kozyavkina NV, Gozhenko OA, Gozhenko AI, Barylyak LG, Popovych IL. Bioactive Water Naftussya and Neuro-Endocrine-Immune Complex [in Ukrainian]. Kyiv. UNESCO-SOCIO; 2015: 349.

22. Polovynko IS, Zayats LM, Zukow W, Popovych IL. Neuro-endocrine-immune relationships by chronic stress at male rats. Journal of Health Sciences. 2013; 3(12): 365-374.

23. Popovych IL. Factor and canonical analyzes of the parameters of the neuro-endocrine-immune complex, metabolism and erosive-ulcerative lesions of the gastric mucosa in rats under acute water-immersion stress [in Ukrainian]. Medical Hydrology and Rehabilitation. 2007; 5(2): 68-80.

24. Popovych IL. Functional interactions between neuroendocrine-immune complex in male rats [in Ukrainian]. Achievements of Clinical and Experimental Medicine. 2008; 2(9): 80-87.

25. Popovych IL. Stresslimiting Adaptogene Mechanism of Biological and Curative Activity of Water Naftussya [in Ukrainian]. Kyiv. Computerpress; 2011: 300.

26. Popovych IL, Gozhenko AI, Zukow W, Polovynko IS. Variety of Immune Responses to Chronic Stress and their Neuro-Endocrine Accompaniment. Scholars' Press. Riga: 2020: 172.

27. Popovych IL, Kozyavkina NV. Metabolic accompaniment of thyrotropic effects of bioactive water Naftussya in women with thyroid hyperplasia [in Ukrainian]. Medical Hydrology and Rehabilitation. 2012; 10(4): 114-138.

28. Popovych IL, Vis’tak HI, Gumeqa MD, Ruzhylo SV. Vegetotropic Effects of Bioactive Water Naftussya and their Endocrine-Immune, Metabolic and Hemodynamic Accompaniments [in Ukrainian]. Kyiv. UNESCO-SOCIO; 2014: 163.

29. Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017; 5: 258.

30. Struk ZD. Neuroendocrine and clinical accompaniments of multivariate immunotropic effects of bioactive water Naftussya [in Ukrainian]. Medical Hydrology and Rehabilitation. 2009; 7(4): 51-65.

31. Vis’tak HI, Popovych IL. Vegetotropic effects of bioactive water Naftussya and their endocrine and immune support in female rats [in Ukrainian]. Medical Hydrology and Rehabilitation. 2011; 9(2): 39-57.